X T L Biopharmaceuticals reported $946.24M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Alaunos Therapeutics USD 2.49M 108K Jun/2026
Bioline Rx USD 2.62B 10.16M Jun/2026
Teva Pharmaceutical Industries USD 1.17B 2M Sep/2026
X T L Biopharmaceuticals USD 946.24M 64.86M Dec/2025